

M.H

**PCT**

WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification <sup>7</sup> :</b> <b>A61K 47/48</b>		<b>A2</b>	<b>(11) International Publication Number:</b> <b>WO 00/10611</b>
			<b>(43) International Publication Date:</b> 2 March 2000 (02.03.00)
<b>(21) International Application Number:</b> PCT/GB99/02620 <b>(22) International Filing Date:</b> 19 August 1999 (19.08.99)  <b>(30) Priority Data:</b> 9818030.0 19 August 1998 (19.08.98) GB 9818156.3 20 August 1998 (20.08.98) GB  <b>(71) Applicant (for all designated States except US):</b> THERAMARK LIMITED [GB/GB]; 90 Fetter Lane, London EC4A 1JP (GB).  <b>(72) Inventors; and</b> <b>(75) Inventors/Applicants (for US only):</b> FREEMAN, Sally [GB/GB]; 3 Riddings Road, Hale, Altrincham, Cheshire WA15 9DS (GB). JAFFER, Mohammed [GB/GB]; Flat 12, Everett Road, Everett Court, Withington, Manchester M20 3DY (GB). STRATFORD, Ian [GB/GB]; Bretton Cottage, Bretton, Eyam, Hope Valley, Derbyshire S32 5QD (GB).  <b>(74) Agent:</b> ATKINSON, Peter, Birch; Marks & Clerk, Sussex House, 83-85 Mosley Street, Manchester M2 3LG (GB).			<b>(81) Designated States:</b> AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).  <b>Published</b> <i>Without international search report and to be republished upon receipt of that report.</i>
<b>(54) Title:</b> DRUG TARGETING			
<b>(57) Abstract</b> <p>A bioreductive conjugate comprises a bioreductive moiety with at least one therapeutic agent linked thereto and physiologically acceptable derivatives thereof. The bioreductive moiety incorporates an aromatic ring substituted with a nitro group and the conjugate is such that bioreduction of the nitro group causes release of the therapeutic agent by a through bond elimination and the residue of the bioreductive moiety to undergo an intramolecular cyclisation reaction in which the nitrogen of the original nitro group provides an atom of the thus formed ring.</p>			